Skip to main content

References

References

  1. Medical Services Advisory Committee. Clinical Utility Card for heritable mutations which increase risk in breast and/or ovarian cancer. 2015 [May 2017; Available from: http://msac.gov.au/internet/msac/publishing.nsf/Content/D3E96917F7B2253BCA25801000123C2E/$File/1411.1_CUC-BreastOvarianCancerGeneticTesting.pdf.]
  2. eviQ. Genetic Testing for Heritable Mutations in the BRCA1 and BRCA2 Genes. Literature Search tab. 2017 [Available from: https://www.eviq.org.au/Protocol/tabid/66/categoryid/440/id/620/Genetic+Testing+for+Heritable+Mutations+in+the+BRCA1+and+BRCA2+Genes.aspx.]
  3. Cancer Australia. Ovarian cancer statistics 2017 [Available from: https://ovarian-cancer.canceraustralia.gov.au/statistics.]
  4. Rosen DG, Yang G, Liu G, et al. Ovarian cancer: pathology, biology, and disease models. Front Biosci (Landmark Ed). 2009;14:2089-102.
  5. Lancaster JM, Powell CB, Chen LM, et al. Society of Gynecologic Oncology statement on risk assessment for inherited gynecologic cancer predispositions. Gynecol Oncol. 2015;136(1):3-7.
  6. Vergote I, Banerjee S, Gerdes AM, et al. Current perspectives on recommendations for BRCA genetic testing in ovarian cancer patients. Eur J Cancer. 2016;69:127-34.
  7. Alsop K, Fereday S, Meldrum C, et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J Clin Oncol. 2012;30(21):2654-63.
  8. Trainer AH, Meiser B, Watts K, et al. Moving toward personalized medicine: treatment-focused genetic testing of women newly diagnosed with ovarian cancer. Int J Gynecol Cancer. 2010;20(5):704-16.
  9. Arts-de Jong M, de Bock GH, van Asperen CJ, et al. Germline BRCA1/2 mutation testing is indicated in every patient with epithelial ovarian cancer: A systematic review. Eur J Cancer. 2016;61:137-45.
  10. Norquist BM, Harrell MI, Brady MF, et al. Inherited Mutations in Women With Ovarian Carcinoma. JAMA Oncol. 2016;2(4):482-90.
  11. Vicus D, Finch A, Cass I, et al. Prevalence of BRCA1 and BRCA2 germ line mutations among women with carcinoma of the fallopian tube. Gynecol Oncol. 2010;118(3):299-302.
  12. George A, Riddell D, Seal S, et al. Implementing rapid, robust, cost-effective, patient-centred, routine genetic testing in ovarian cancer patients. Sci Rep. 2016;6:29506.
  13. Malander S, Ridderheim M, Masback A, et al. One in 10 ovarian cancer patients carry germ line BRCA1 or BRCA2 mutations: results of a prospective study in Southern Sweden. Eur J Cancer. 2004;40(3):422-8.
  14. Plaskocinska I, Shipman H, Drummond J, et al. New paradigms for BRCA1/BRCA2 testing in women with ovarian cancer: results of the Genetic Testing in Epithelial Ovarian Cancer (GTEOC) study. J Med Genet. 2016;53(10):655-61.
  15. Walsh T, Casadei S, Lee MK, et al. Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Proc Natl Acad Sci U S A. 2011;108(44):18032-7.
  16. Bahar AY, Taylor PJ, Andrews L, et al. The frequency of founder mutations in the BRCA1, BRCA2, and APC genes in Australian Ashkenazi Jews: implications for the generality of U.S. population data. Cancer. 2001;92(2):440-5.
  17. Risch HA, McLaughlin JR, Cole DE, et al. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. J Natl Cancer Inst. 2006;98(23):1694-706.
  18. Janavicius R. Founder BRCA1/2 mutations in the Europe: implications for hereditary breast-ovarian cancer prevention and control. EPMA J. 2010;1(3):397-412.
  19. Amir E, Freedman OC, Seruga B, et al. Assessing women at high risk of breast cancer: a review of risk assessment models. J Natl Cancer Inst. 2010;102(10):680-91.
  20. Antoniou AC, Hardy R, Walker L, et al. Predicting the likelihood of carrying a BRCA1 or BRCA2 mutation: validation of BOADICEA, BRCAPRO, IBIS, Myriad and the Manchester scoring system using data from UK genetics clinics. J Med Genet. 2008;45(7):425-31.
  21. Evans DG, Harkness EF, Plaskocinska I, et al. Pathology update to the Manchester Scoring System based on testing in over 4000 families. J Med Genet. 2017;doi: 10.1136/jmedgenet-2017-104584. [Epub ahead of print].
  22. Committee on Practice Bulletins-Gynecology, and the Society of Gynecologic Oncology. ACOG Practice Bulletin No. 147: Lynch syndrome. Obstet Gynecol. 2014;124(5):1042-54.
  23. eviQ. Cancer Treatments Online. Referral guidelines for ovarian cancer risk assessment and consideration of genetic testing. 2016 [cited 2017. Available from: https://www.eviq.org.au/Protocol/tabid/66/id/1905/Default.aspx?popup=1.]
  24. Graffeo R, Livraghi L, Pagani O, et al. Time to incorporate germline multigene panel testing into breast and ovarian cancer patient care. Breast Cancer Res Treat. 2016;160(3):393-410.
  25. Society of Gynecologic Oncology. SGO Clinical Practice Statement: Next Generation Cancer Gene Panels Versus Gene by Gene Testing 2014 [Available from: https://www.sgo.org/clinical-practice/guidelines/next-generation-cancer-gene-panels-versus-gene-by-gene-testing/.]
  26. National Comprehensive Cancer Network. NCCN Clinical practice guidelines in Oncology. Genetic/familial high-risk assessment: Breast and Ovarian. Ver 2.2017 – December 2016 2016 [Available from: https://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf.]
  27. Hoogerbrugge N, Jongmans MC. Finding all BRCA pathogenic mutation carriers: best practice models. Eur J Hum Genet. 2016;24 Suppl 1:S19-26.
  28. Pinto C, Bella MA, Capoluongo E, et al. Recommendations for the implementation of BRCA testing in the care and treatment pathways of ovarian cancer patients. Future Oncol. 2016;12(18):2071-5.
  29. George A, Kaye S, Banerjee S. Delivering widespread BRCA testing and PARP inhibition to patients with ovarian cancer. Nat Rev Clin Oncol. 2017; 14(5):284-296.
  30. Ledermann JA, Harter P, Gourley C, et al. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. Lancet Oncol. 2016;17(11):1579-89.
  31. Mirza MR, Monk BJ, Herrstedt J, et al. Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. N Engl J Med. 2016;375(22):2154-64.
  32. Suthers GK. Cancer risks for Australian women with a BRCA1 or a BRCA2 mutation. ANZ J Surg. 2007;77(5):314-9.
  33. Cancer Australia. Advice about familial aspects of breast cancer and epithelial ovarian cancer. 2010 [Available from: https://canceraustralia.gov.au/publications-and-resources/cancer-australia-publications/advice-about-familial-aspects-breast-cancer-and-epithelial-ovarian-cancer.]
  34. Cancer Australia. Early detection of breast cancer. 2015 [Available from: https://canceraustralia.gov.au/publications-and-resources/position-statements/early-detection-breast-cancer.]
  35. Cancer Australia. Surveillance of women at high or potentially high risk of ovarian cancer. 2009 [Available from: https://canceraustralia.gov.au/publications-and-resources/position-statements/surveillance-women-high-or-potentially-high-risk-ovarian-cancer.]
  36. Cancer Australia. Recommendations for management of women at high risk of ovarian cancer 2011 [Available from: https://canceraustralia.gov.au/publications-and-resources/clinical-practice-guidelines/recommendations-management-women-high-risk-ovarian-cancer.]
  37. Kentwell M, Dow E, Antill Y, et al. Mainstreaming cancer genetics: A model integrating germline BRCA testing into routine ovarian cancer clinics. Gynecol Oncol. 2017; 145(1):130-136.